(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number
WO 02/088095 A1

(51) International Patent Classification[7]: C07D 239/70, A61K 31/517, C07D 487/04, 471/04, A61K 31/519, A61P 25/00

(21) International Application Number: PCT/GB02/02029

(22) International Filing Date: 30 April 2002 (30.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0110569.1	30 April 2001 (30.04.2001)	GB
0110567.5	30 April 2001 (30.04.2001)	GB
0110570.9	30 April 2001 (30.04.2001)	GB
0117399.6	17 July 2001 (17.07.2001)	GB
0117420.0	17 July 2001 (17.07.2001)	GB
0117401.0	17 July 2001 (17.07.2001)	GB
0203201.9	11 February 2002 (11.02.2002)	GB
0206834.4	22 March 2002 (22.03.2002)	GB

(71) Applicants *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). **DI FABIO, Romano** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CAPELLI, Anna, Maria** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **MARCHIONNI, Chiara** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **MICHELI, Fabrizio** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **PASQUARELLO, Alessandra** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **PERINI, Benedetta** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **ST-DENIS, Yves** [CA/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT).

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/088095 A1

(54) Title: FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF)



(I)

(57) Abstract: The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof wherein the variables are as defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).